atrasentan has been researched along with pyrazines in 2 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (pyrazines) | Trials (pyrazines) | Recent Studies (post-2010) (pyrazines) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 12,165 | 1,373 | 5,747 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nelson, JB; Smith, MR | 1 |
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 1 |
1 review(s) available for atrasentan and pyrazines
| Article | Year |
|---|---|
Future therapies in hormone-refractory prostate cancer.
Topics: Antibodies, Monoclonal; Atrasentan; Boronic Acids; Bortezomib; Diphosphonates; DNA, Antisense; Forecasting; Humans; Immunotherapy; Male; Prostatic Neoplasms; Pyrazines; Pyrrolidines; Receptors, Growth Factor; Thalidomide | 2005 |
1 other study(ies) available for atrasentan and pyrazines
| Article | Year |
|---|---|
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D | 2006 |